Title: Prognostic Factors for the Efficacy of Infliximab in Patients with Luminal Fistulizing
Crohn’s Disease
Version: 3 Date: 31 Jan 2023
Reviewer's report:
I appreciate authors for reappraising their manuscript. their are few corrections required
1. Would suggest to change   Prognostic markers instead of Prognosis in Aim of the study and
revise Prognosis factors to Prognostic Factors. ( Introduction Para 4)
1.  Manuscript says "According to the CDAI score, 9 cases were in clinical remission stage
(CDAI<150 points), 13 cases were in a mild active stage (150#CDAI<220 points), and 4 cases
were in moderate-to-severe active stage (CDAI#220 points) at baseline"
However the table 1 baseline disease activity may need corrections.
2. authors may want to correct this statement as non availability
"Due to the availability of data, serum IL-6 and TNF-# level and other indicators were not
collected and included in the analysis. Serum IFX concentration were also not included:
3. In Discussion BMI is written as BWI
4. Would suggest tailoring of discussion to according to the results of the study. Found very
limited discussion on secondary outcome of the study
5. 9 cases were in clinical remission at baseline and 12 cases in clinical remission at 3 and 6
months was in 12 and 14 respectively. How was remission assessed in such cases.
Title: Prognostic Factors for the Efficacy of Infliximab in Patients with Luminal Fistulizing
Crohn’s Disease
Version: 3 Date: 31 Jan 2023
Reviewer's report:
I appreciate authors for reappraising their manuscript. their are few corrections required
1. Would suggest to change   Prognostic markers instead of Prognosis in Aim of the study and
revise Prognosis factors to Prognostic Factors. ( Introduction Para 4)
1.  Manuscript says "According to the CDAI score, 9 cases were in clinical remission stage
(CDAI<150 points), 13 cases were in a mild active stage (150#CDAI<220 points), and 4 cases
were in moderate-to-severe active stage (CDAI#220 points) at baseline"
However the table 1 baseline disease activity may need corrections.
2. authors may want to correct this statement as non availability
"Due to the availability of data, serum IL-6 and TNF-# level and other indicators were not
collected and included in the analysis. Serum IFX concentration were also not included:
3. In Discussion BMI is written as BWI
4. Would suggest tailoring of discussion to according to the results of the study. Found very
limited discussion on secondary outcome of the study
5. 9 cases were in clinical remission at baseline and 12 cases in clinical remission at 3 and 6
months was in 12 and 14 respectively. How was remission assessed in such cases.
Please review this paper.
user
Title: Prognostic Factors for the Efficacy of Infliximab in Patients with Luminal Fistulizing
Crohn’s Disease
Version: 3 Date: 31 Jan 2023
Reviewer's report:
I appreciate authors for reappraising their manuscript. their are few corrections required
1. Would suggest to change   Prognostic markers instead of Prognosis in Aim of the study and
revise Prognosis factors to Prognostic Factors. ( Introduction Para 4)
1.  Manuscript says "According to the CDAI score, 9 cases were in clinical remission stage
(CDAI<150 points), 13 cases were in a mild active stage (150#CDAI<220 points), and 4 cases
were in moderate-to-severe active stage (CDAI#220 points) at baseline"
However the table 1 baseline disease activity may need corrections.
2. authors may want to correct this statement as non availability
"Due to the availability of data, serum IL-6 and TNF-# level and other indicators were not
collected and included in the analysis. Serum IFX concentration were also not included:
3. In Discussion BMI is written as BWI
4. Would suggest tailoring of discussion to according to the results of the study. Found very
limited discussion on secondary outcome of the study
5. 9 cases were in clinical remission at baseline and 12 cases in clinical remission at 3 and 6
months was in 12 and 14 respectively. How was remission assessed in such cases.
assistant